EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Survival improvements in patients with melanoma brain metastases and leptomeningeal disease in the modern era: Insights from a nationwide study (2015–2022)

Sidsel Pedersen, Emma Lund Johansen, Karen Louise Højholt, Marie Wett Pedersen, Anne Mark Mogensen, Søren Kjær Petersen, Charlotte Aaquist Haslund, Marco Donia, Henrik Schmidt, Lars Bastholt, Rasmus Friis, Inge Marie Svane und 1 weitere

European Journal of Cancer · 2025

DOI: 10.1016/j.ejca.2025.115253 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Sidsel Pedersen und 12 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark. Hauptthemen laut MEDLINE: Melanoma, Brain Neoplasms, Meningeal Neoplasms, Skin Neoplasms. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: F Hoffmann-La Roche Ltd, Pierre Fabre Foundation, Bristol-Myers Squibb Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaBrain NeoplasmsMeningeal NeoplasmsSkin NeoplasmsHumansFemaleMaleMiddle AgedAgedDenmarkAdultAged, 80 and overImmune Checkpoint InhibitorsRetrospective Studies

Stichwörter der Autor:innen

ImmunotherapyLeptomeningeal diseaseMelanoma brain metastasesPostoperative stereotactic radiosurgeryReal-world evidenceTargeted therapy

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.
  • Department of Oncology, Odense University Hospital, Odense, Denmark.
  • Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Oncology, Aalborg University Hospital, Aalborg, Denmark.
  • National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark. Electronic address: eva.ellebaek.steensgaard@regionh.dk.

Förderung

  • F Hoffmann-La Roche Ltd
  • Pierre Fabre Foundation
  • Bristol-Myers Squibb Company
  • MSD
  • Novartis AG

Zitieren

APA

Pedersen, S., Johansen, E. L., Højholt, K. L., Pedersen, M. W., Mogensen, A. M., Petersen, S. K., Haslund, C. A., Donia, M., Schmidt, H., Bastholt, L., Friis, R., Svane, I. M., & Ellebaek, E. (2025). Survival improvements in patients with melanoma brain metastases and leptomeningeal disease in the modern era: Insights from a nationwide study (2015–2022). European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115253

Vancouver

Pedersen S, Johansen EL, Højholt KL, Pedersen MW, Mogensen AM, Petersen SK, et al. Survival improvements in patients with melanoma brain metastases and leptomeningeal disease in the modern era: Insights from a nationwide study (2015–2022). European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.115253

BibTeX
@article{Pedersen2025,
  author = {Pedersen, Sidsel and Johansen, Emma Lund and Højholt, Karen Louise and Pedersen, Marie Wett and Mogensen, Anne Mark and Petersen, Søren Kjær and Haslund, Charlotte Aaquist and Donia, Marco and Schmidt, Henrik and Bastholt, Lars and Friis, Rasmus and Svane, Inge Marie and Ellebaek, Eva},
  title = {Survival improvements in patients with melanoma brain metastases and leptomeningeal disease in the modern era: Insights from a nationwide study (2015–2022)},
  journal = {European Journal of Cancer},
  year = {2025},
  doi = {10.1016/j.ejca.2025.115253}
}
Kostenlos starten →